The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
about
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populationsThe role of drug transporters in the kidney: lessons from tenofovirTowards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulationsPharmacokinetic drug-drug interaction and their implication in clinical managementDiscovery and characterization of a potent and selective inhibitor of Aedes aegypti inward rectifier potassium channelsThe role of oseltamivir in the treatment and prevention of influenza in children.Pharmacokinetics and tolerability of oseltamivir combined with probenecid.Oseltamivir in human avian influenza infection.Combination chemotherapy for influenza.Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.Development and validation of a high-throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies.Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza.An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report.Species-dependent uptake of glycylsarcosine but not oseltamivir in Pichia pastoris expressing the rat, mouse, and human intestinal peptide transporter PEPT1.Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies.The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometricsTargeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteersPharmacokinetics of high-dose oseltamivir in healthy volunteers.siRNA Genome Screening Approaches to Therapeutic Drug Repositioning.Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.Importance of drug transporters in pharmacokinetics and drug safety.The history and future of probenecid.Pharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.Oseltamivir for the treatment of H1N1 influenza during pregnancy.Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.Renal Drug Transporters and Drug Interactions.Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study.Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects.Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.Population pharmacokinetics of oseltamivir when coadministered with probenecid.Potential adverse effects of oseltamivir in rats: males are more vulnerable than females.Optimization of polymerization parameters for the sorption of oseltamivir onto molecularly imprinted polymers.Dystrophic cardiomyopathy: role of TRPV2 channels in stretch-induced cell damage.Oseltamivir for treatment and prophylaxis of influenza infectionSolute Carrier (SLC) Family Transporters
P2860
Q24630906-A3B87EC3-AFEA-4DD4-A31E-569951718F4EQ26866489-EEAD1D8E-58D1-4C84-9A63-6C97D13F0AF2Q27020967-60FC829A-758D-4F47-9108-006569330D46Q27021051-FF1258C4-B2E0-4F6D-8AD8-BC8D109B7738Q28544756-00C01A1D-1C2C-41FA-A356-B5999CB8B14FQ30364977-94E7F661-4A63-43CD-AD64-999BE6B4CF78Q30370031-2885313F-2626-404C-9B6B-52447BE659A1Q30386487-7B046F1B-1331-4678-8271-9433396E5E6BQ30408112-76943E64-5739-4824-8F8E-4AE760AD5CA6Q30409023-2984E5B6-7A68-4B01-878A-0E3FCBCE1069Q33693650-3EEA26F2-7788-4B27-9526-38E51204F5CEQ34109232-416E58B4-F851-41BD-B9F8-5A400C657D96Q34158669-3E6FDD20-9BCA-47A6-82A6-018A1DA37DF5Q35191600-089B7D1E-4D38-4B23-8DE8-F8329105B5AFQ35737905-BE7EB358-DB9C-4939-9272-DC88758481FBQ36057398-F3B1944D-81EF-41FC-B78F-1101BFE48F3BQ36105344-E3824ECE-C5C3-4BD0-9A08-316768763133Q36468109-37F03695-E189-4116-A426-D387A0106C07Q36505517-232FEC76-E9B5-41B1-90AF-E6D9C49485A8Q36932915-E3EFCB2F-F992-4EF4-8EFD-744526EC1D07Q37115683-5EF7106D-D685-441B-85FA-2BEE03BC4C35Q37277365-7D3C9032-BF41-45BB-8D82-98B15CF5967DQ37409972-699B86E0-1260-4E1B-81DB-6397E5FD1F27Q37658682-820D2E5F-D717-4C3C-A0F5-1439284ECCB8Q37936912-7666B077-3295-454E-9668-40667B26935AQ38024126-EF3955BE-D6A0-49BE-8492-0515E8DE0BE4Q38084212-99C0F6AD-E438-4F20-8E1A-E5F7AABDEA07Q38214334-859AFD62-FE5D-469A-B4FA-FF0A33F2EBC5Q38537284-08C44FD1-8AF6-4A47-A485-57523AB3D9EEQ38844658-142BE718-D8D0-44BD-8BC2-AC7885AC5F85Q39140289-39D88D5C-6500-4466-89BD-0301C394836CQ42622839-B06ED6E4-C067-4118-B31B-302CE64C8330Q43176322-52F85E33-14F7-4B27-9EC8-5B3A9C8476BBQ43663687-2016D20B-FD03-4AE7-BA0E-8FFAF41A4425Q46558714-256C7CA3-8028-407D-996C-99858402D2E1Q51422981-4899B770-271C-47F1-B5FE-EE1ADDF168D4Q51570685-425C0F2D-2354-4CEA-8E0A-89FD5457C97FQ53636857-B0CD1D1D-316F-424A-A675-DBAAC929215CQ56785849-D76D64AE-8A2A-4EA2-87F6-B196724998C5Q57684555-9C5C254B-E4EE-4E86-AC00-35C4A3900FEA
P2860
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The anti-influenza drug oselta ...... in vivo and in vitro studies.
@ast
The anti-influenza drug oselta ...... in vivo and in vitro studies.
@en
type
label
The anti-influenza drug oselta ...... in vivo and in vitro studies.
@ast
The anti-influenza drug oselta ...... in vivo and in vitro studies.
@en
prefLabel
The anti-influenza drug oselta ...... in vivo and in vitro studies.
@ast
The anti-influenza drug oselta ...... in vivo and in vitro studies.
@en
P2093
P356
P1476
The anti-influenza drug oselta ...... f in vivo and in vitro studies
@en
P2093
Baulian Liu
Edmund S Ho
George Hill
Hugh Wiltshire
Jo Barrett
Tomas Cihlar
P356
10.1124/DMD.30.1.13
P577
2002-01-01T00:00:00Z